The present study was designed to investigate the concentrations of carbon monoxide (CO) in the anaesthetic circuit and of arterial carboxyhaemoglobin (COHb) during low-flow isoflurane anaesthesia in smoking and non-smoking subjects using three kinds of cardon dioxide (CO 2 ) absorbent. Thirty smoking and 30 non-smoking subjects were selected for this study, and these two groups were each divided into three groups according to the type of CO 2 absorbent used (Wakolime™ A, Drägersorb™ Free, and Amsorb™). Anaesthesia was maintained with 1.0% isoflurane and nitrous oxide (1.0l min -1 )/oxygen (1.0l min -1 ). Concentrations of CO in the inspired breathing circuit and concentrations of arterial COHb were measured at 0, 1, 2, 3, and 4 hours after exposure to isoflurane. In the smoking groups there were no significant differences in CO concentrations in the circuit between the groups and the CO concentrations did not change significantly during the study period. There were also no significant differences in the arterial COHb values between the groups and the COHb concentrations remained constant. There was a significant linear correlation between the concentrations of CO and COHb (r=0.86, n=30, P<0.001). In the nonsmoking groups all of the parameters remained constant at low levels that were independent of the type of CO 2 absorbents tested. The major source for increased intraoperative CO exposure is related to the patient's smoking status, and the type of CO 2 absorbent used has no relation to an increase in CO concentration in the breathing circuit.
Despite warnings of the health hazards of cigarette smoking, still one third of the population in industrial countries smoke 1 . Smokers have a high incidence of postoperative respiratory complications such as pneumonia 2, 3 , and smoking can also increase the concentration of carboxyhemoglobin (COHb) up to 5% to 10% 4 , a concentration that inhibits the preferred binding of haemoglobin (Hb) with oxygen, leading to cardiac events during anaesthesia 5 . On the other hand, carbon monoxide (CO) can be produced from degradation of isoflurane by soda lime 6 , especially with dry soda lime 6, 7 , or by the use of a low-flow anaesthetic technique 7, 8 . An unfavourable increase in COHb in smoking patients is therefore anticipated under these conditions. The production of CO is directly related to the presence of monovalent hydroxide bases such as NaOH and KOH contained in conventional absorbents 9, 10 . Some carbon dioxide (CO 2 ) absorbents that contain few or no strong bases have become available for clinical use 10, 11 . We therefore investigated the concentration of CO in the anaesthetic circuit and the concentration of arterial COHb during low-flow isoflurane anaesthesia in smoking and non-smoking subjects using various kinds of CO 2 absorbents with and without strong bases.
METHODS
This study was approved by the Institutional Ethics Committee on Human Research and informed consent was obtained from each patient. Sixty ASA physical status 1 or 2 adult patients who had been scheduled to receive isoflurane for general anaesthesia anticipated to last four hours or longer were enrolled in this study. Patients with a history or other evidence of hepatic, renal, or significant cardiovascular disease were excluded from the study. Thirty patients who were smoking up to the operating date more than five cigarettes per day were selected for the study as a smoker group, and 30 patients who had never smoked were selected as a non-smoker group. Atropine 0.5 mg and midazolam (2 to 3 mg) were given I.M. one hour preoperatively.
Anaesthesia was induced with propofol 2 to 3 mg.kg -1 and fentanyl 1 to 2 µg.kg -1 IV, and muscle paralysis was induced by 0.15 mg.kg -1 vecuronium IV. After tracheal intubation, anaesthesia was maintained with isoflurane and nitrous oxide (1.0 l.min -1 ) and oxygen (1.0 l.min -1 ) with fentanyl 1 to 2 µg.kg -1 in incremental doses as required to maintain systolic arterial blood pressure within ±20% of the preanaesthetic baseline value. Ventilation was controlled with a tidal volume of 10 to 12 ml.kg -1 with the ventilatory rate adjusted to maintain end-tidal CO 2 partial pressure (P ET CO 2 ) between 34 and 38 mmHg. The anaesthetic machine used was a Cicero™ low-flow anaesthetic machine (Dräger, Lübeck, Germany). The circle system hoses were made of silicone rubber. The Y-piece was made of polypropylene. The other components of the circle system (valves, fresh gas inlet, canister etc) were the standard components used in the Cicero anaesthetic machine. The endtidal isoflurane concentrations were adjusted as indicated by the built-in calibrated gas monitor (PM8020, Dräger) to 1.0%.
The patients, both smokers and non-smokers, were each randomly (envelope technique) assigned to one of three groups according to the type of CO 2 absorbent used. The CO 2 absorbents used were Wakolime™ A (Wako Pure Chemical, Osaka, Japan), Drägersorb™ Free (Dräger), and Amsorb™ (Armstrong, Coleraine, Northern Ireland) 10 . Compositions of the CO 2 absorbents used are listed in Table 1 . Fresh CO 2 absorbents and a new circle system were used for each patient. Gas samples for measurement of CO were obtained from the inspiratory limb of the circle system at 0, 1, 2, 3, and four hours after exposure to isoflurane. The design of the CO monitor used in this study is based on an electrochemical oxidation principle (Carbolyzer™ mBA-2000; Taiyo Co., Osaka, Japan), which enables measurement of CO concentrations without interference of anaesthetic gases used simultaneously. It has a detection range of 0 to 50 ppm (minimum as 0.1 ppm), and routine calibration of the CO monitor was performed according to the manufacturer's instructions. An automatic suction pump was involved in this machine, drawing approximately 200 ml.min -1 of gas from the inspiratory limb, and it was then returned to the circuit. Concentrations of arterial COHb were measured at the same time as the measurement of CO concentrations in the breathing circuit. Briefly, arterial blood samples were obtained from a catheter inserted into the left radial artery. The concentrations of COHb in the blood samples were measured by the use of a calibrated blood gas analysis apparatus (ABL 700™, Radiometer, Tokyo, Japan).
Data are expressed as means±SD or ±SEM, or scatter diagrams. Power analysis (α=0.01, β=0.1) provided an appropriate sample size of range between 10 and 15. Concentrations of CO in the breathing circuit and arterial COHb were compared using linear regression analysis. The regression slopes were compared to analyze differences in relation of CO and COHb between groups. Other data (e.g., time course of the changes in CO/COHb, CO/COHb between the groups) were analysed using one-way ANOVA for repeated measurements, and Fisher's test was used as a post hoc test. In all comparisons, P<0.05 was considered significant.
RESULTS
All six groups were comparable with respect to gender, age, body weight, body mass index, ASA physical status, and P ET CO 2 ( Table 2 ). In the smoker groups, the time courses of changes in concentrations of CO in the inspired breathing circuit (A) and of changes in concentrations of arterial COHb (B) during the study are shown in Figure 1 . CO concentrations in the breathing circuit at the beginning of this study ranged from 3.1 to 48.2 ppm. Although the CO concentrations in the Wakolime™A group seemed to be a little higher than those in the other two groups, there was no significant difference between the groups (P=0.54~0.64), and the CO concentrations in the breathing circuit did not change significantly during the study period in either group (P=0.62~0.74). Similar phenomena were observed in the concentrations of arterial COHb; there was no significant difference between the groups (P=0.690 .82), and the COHb concentrations did not change significantly in either group (P=0.78~0.81). Comparisons of CO concentrations in the breathing circuit and arterial COHb concentrations at the beginning of this study are shown in Figure 2 . There was a significant linear correlation between these parameters (r=0.86, n=30, P<0.001), and the strong correlation did not change throughout the study period (1, 2, 3, and 4 hours after isoflurane exposure, r=0.84~0.91, raw data not shown). There was no significant difference in the correlation between groups of type of CO 2 absorbents (P=0.56~0.64).
In the non-smoker groups, the time courses of 232 changes in concentrations of CO in the inspired breathing circuit (A) and of changes in concentrations of arterial COHb (B) during the study are shown in Figure 3 . CO concentrations in the breathing circuit at the beginning of this study ranged from 0.6 to 4.3 ppm. There were no significant differences in the CO concentrations or in the COHb concentrations between the groups (P=0.71~0.92). These parameters did not change significantly during the study period (P=0.73~0.84). There was no significant correlation between these parameters and between the groups (P=0.67~0.88, raw data not shown).
DISCUSSION
This study showed that the concentrations of CO in the inspired breathing circuit had a strong correlation with the concentrations of blood COHb in smoking subjects (Figure 2 ). The fact that the CO concentrations in the breathing circuit did not change throughout the study period (Figure 1) indicates that the CO was mainly derived from the patients. This can be supported by the fact that CO concentrations in the non-smoker group did not increase at all and remained at very low levels irrespective of the type of CO 2 absorbent tested. There is a report that only a small amount of CO is produced by haemoglobin metabolism 8 . Therefore, the CO measured in this study depends mainly on cigarette smoking per se. Tang et al 12 reported similar results showing that the probability of an increased CO concentration in the breathing circuit is higher in chronic smokers than in nonsmokers, and that acute preoperative smoking also resulted in excess CO exposure for smokers. CO has a 200-times higher affinity for Hb than does oxygen, shifts the oxyhemoglobin dissociation curve to the left 13 , and inhibits aerobic metabolism by binding with cytochrome oxidase 14 . For these reasons, intracellular O 2 transport and usage in important organs are reduced, which may result in tissue hypoxia. It is well known that arrhythmias can be produced by elevated COHb in patients with coronary artery disease 15 . Because the biological half-life of COHb is approximately 4 to 6 hrs, depending mainly on the ventilatory volume 16 , it is recommended that patients stop smoking at least 24 hours before an operation.
We also found in this study that CO production did not depend on the type of CO 2 absorbent. Even though the conventional CO 2 absorbent Wakolime™ A contains the strong bases NaOH and KOH, it did not increase the concentrations of CO, which leads to an increase in COHb. Bonome et al 7 reported that fresh gas flow had a diluting effect on CO concentrations in the circuit. Tang et al 12 also reported results of analysis using a regression model that predicted decreases of approximately 7.7 ppm and 5.9 ppm in peak and mean CO concentrations for an increase in gas flow rate by 1.0 l.min -1 . They recommended that an increase in gas flow should be considered during anaesthesia for smoking patients. Because the use of a low-flow anaesthetic technique has a humidifying effect, which can reduce the CO production by soda lime 7 , and because neither the concentrations of CO in the breathing circuit nor the COHb concentrations increased in this study, it is permissible to use 2.0 l.min -1 fresh gas flow even in smoking patients and even when the conventional soda lime with strong bases is used.
In conclusion, the major sources for increased intraoperative CO exposure are related to patient attributes, such as smoking status and number of cigarettes smoked before the operation. The results of this study, showing that the type of CO 2 absorbent and the use of a low-flow anaesthetic technique (2.0 l.min -1 ) were not related to an increase in CO concentrations in the breathing circuit, indicate that FIGURE 2: Correlation between CO concentrations in the breathing circuit (ppm) and arterial COHb concentrations (%) at the beginning of this study in the smoking groups. Wakolime™ A (Wako Pure Chemical, Osaka, Japan) ( ), Drägersorb™ Free (Dräger, Lübeck, Germany) ( ), and Amsorb™ (Armstrong, Coleraine, Northern Ireland) ( ). There was a significant linear correlation between these parameters (r=0.86, n=30, P<0.001). There were no significant differences in the correlation between groups of type of CO2 absorbents (P=0.56~0.64).
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